Cardiometabolic risk in polycystic ovary syndrome

被引：42
|
作者：
Studen, Katica Bajuk [1 ]
Pfeifer, Marija [2 ]
机构：
[1] Univ Med Ctr Ljubljana, Nucl Med Dept, Ljubljana, Slovenia
[2] Univ Ljubljana, Fac Med, Ljubljana, Slovenia
来源：
ENDOCRINE CONNECTIONS | 2018年 / 7卷 / 07期
关键词：
PCOS; cardiovascular risk; cardiometabolic risk; hyperandrogenism; obesity; OBSTRUCTIVE SLEEP-APNEA; IMPAIRED GLUCOSE-TOLERANCE; INTIMA-MEDIA THICKNESS; CORONARY-ARTERY-DISEASE; FATTY LIVER-DISEASE; HORMONE-BINDING GLOBULIN; INSULIN-RESISTANCE; CARDIOVASCULAR-DISEASE; METABOLIC SYNDROME; OBESE WOMEN;
D O I：
10.1530/EC-18-0129
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
Polycystic ovary syndrome (PCOS) is a common disorder in women of reproductive age. Besides hyperandrogenism, oligomenorrhea and fertility issues, it is associated with a high prevalence of metabolic disorders and cardiovascular risk factors. Several genetic polymorphisms have been identified for possible associations with cardiometabolic derangements in PCOS. Different PCOS phenotypes differ significantly in their cardiometabolic risk, which worsens with severity of androgen excess. Due to methodological difficulties, longer time-scale data about cardiovascular morbidity and mortality in PCOS and about possible beneficial effects of different treatment interventions is missing leaving many issues regarding cardiovascular risk unresolved.
引用
收藏
页码：R238 / +
页数：14
相关论文
共 50 条
  • [11] Cardiometabolic features of polycystic ovary syndrome
    Hoffman, Leslie K.
    Ehrmann, David A.
    NATURE CLINICAL PRACTICE ENDOCRINOLOGY & METABOLISM, 2008, 4 (04): : 215 - 222
  • [12] Cardiometabolic Aspects of the Polycystic Ovary Syndrome
    Randeva, Harpal S.
    Tan, Bee K.
    Weickert, Martin O.
    Lois, Konstantinos
    Nestler, John E.
    Sattar, Naveed
    Lehnert, Hendrik
    ENDOCRINE REVIEWS, 2012, 33 (05) : 812 - 841
  • [13] Polycystic Ovary Syndrome-Is the Cardiometabolic Risk Increased After Menopause?
    Dokras, Anuja
    MENOPAUSE-THE JOURNAL OF THE NORTH AMERICAN MENOPAUSE SOCIETY, 2017, 24 (12): : 1421 - 1422
  • [14] Polycystic ovary syndrome and cardiometabolic risk: Opportunities for cardiovascular disease prevention
    Osibogun, Olatokunbo
    Ogunmoroti, Oluseye
    Michos, Erin D.
    TRENDS IN CARDIOVASCULAR MEDICINE, 2020, 30 (07) : 399 - 404
  • [15] VISFATIN AS A POTENTIAL CARDIOMETABOLIC RISK FACTOR IN WOMEN WITH POLYCYSTIC OVARY SYNDROME
    Koleva-Tyutyundzhieva, D.
    Ilieva-Gerova, M.
    Deneva, T.
    Nikolova, J.
    Orbetzova, M.
    ATHEROSCLEROSIS, 2023, 379 : S104 - S104
  • [16] Polycystic ovary syndrome as a gender-specific cardiometabolic risk factor
    van Baal, Lukas
    Tan, Susanne
    INNERE MEDIZIN, 2023, 64 (07): : 642 - 648
  • [17] Advances in cardiometabolic outcomes in polycystic ovary syndrome
    Moran, Lisa J.
    NATURE REVIEWS ENDOCRINOLOGY, 2025, 21 (02) : 67 - 68
  • [18] Cardiometabolic biomarkers in women with polycystic ovary syndrome
    van der Ham, Kim
    Louwers, Yvonne, V
    Laven, Joop S. E.
    FERTILITY AND STERILITY, 2022, 117 (05) : 887 - 896
  • [19] Cardiometabolic risk in polycystic ovary syndrome: a comparison of different approaches to defining the metabolic syndrome
    Cussons, Andrea J.
    Watts, Gerald F.
    Burke, Valerie
    Shaw, Jonathan E.
    Zimmet, Paul Z.
    Stuckey, Bronwyn G. A.
    HUMAN REPRODUCTION, 2008, 23 (10) : 2352 - 2358
  • [20] A Unique Rodent Model of Cardiometabolic Risk Associated with the Metabolic Syndrome and Polycystic Ovary Syndrome
    Shi, Danni
    Dyck, Michael K.
    Uwiera, Richard R. E.
    Russell, Jim C.
    Proctor, Spencer D.
    Vine, Donna F.
    ENDOCRINOLOGY, 2009, 150 (09) : 4425 - 4436
12345